Share Article
- Over 180,000 U.S. and EU Patients Treated Year-to-Date with Sovaldi or Harvoni -
- Product Sales of
- Non-GAAP EPS of
- Revised 2015 Full Year Guidance -
| Three Months Ended | Six Months Ended | |||||||||||
| June 30, | June 30, | |||||||||||
| (In millions, except per share amounts) | 2015 | 2014 | 2015 | 2014 | ||||||||
| Product sales | $ | 8,126 | $ | 6,413 | $ | 15,531 | $ | 11,284 | ||||
| Royalty, contract and other revenues | 118 | 122 | 307 | 250 | ||||||||
| Total revenues | $ | 8,244 | $ | 6,535 | $ | 15,838 | $ | 11,534 | ||||
| Net income attributable to Gilead | $ | 4,492 | $ | 3,656 | $ | 8,825 | $ | 5,883 | ||||
| Non-GAAP net income attributable to Gilead | $ | 4,845 | $ | 3,929 | $ | 9,449 | $ | 6,417 | ||||
| Diluted EPS | $ | 2.92 | $ | 2.20 | $ | 5.68 | $ | 3.52 | ||||
| Non-GAAP diluted EPS | $ | 3.15 | $ | 2.36 | $ | 6.08 | $ | 3.84 | ||||
Product Sales
Total product sales for the second quarter of 2015 were
Antiviral Product Sales
Antiviral product sales increased to
Other Product Sales
Other product sales, which include Letairis® (ambrisentan),
Ranexa® (ranolazine) and AmBisome® (amphotericin B
liposome for injection), were
Operating Expenses
| Three Months Ended | Six Months Ended | |||||||||||
| June 30, | June 30, | |||||||||||
| (In millions) | 2015 | 2014 | 2015 | 2014 | ||||||||
| Non-GAAP research and development expenses | $ | 702 | $ | 542 | $ | 1,353 | $ | 1,100 | ||||
| Non-GAAP selling, general and administrative expenses | $ | 761 | $ | 570 | $ | 1,361 | $ | 1,070 | ||||
Note:Non-GAAP R&D and SG&A expenses exclude amounts related to acquisition, restructuring, stock-based compensation and other.
During the second quarter of 2015, compared to the same period in 2014:
- Non-GAAP research and development (R&D) expenses increased primarily due to the continued progression and expansion of Gilead's clinical studies, particularly Phase 3 studies in the liver disease and oncology areas.
- Non-GAAP selling, general and administrative (SG&A) expenses increased primarily due to an increase in Gilead's portion of the branded prescription drug fee along with growth and the geographic expansion in its business.
Cash,
As of
Revised 2015 Full Year Guidance
Gilead updated its full year 2015 guidance, which it initially provided
on
| (In millions, except percentages and per share amounts) | Initially Provided February 3, 2015 | Updated April 30, 2015 | Updated July 28, 2015 | |||||
| Net Product Sales | $26,000 - $27,000 | $28,000 - $29,000 | $29,000 - $30,000 | |||||
| Non-GAAP* | ||||||||
| Product Gross Margin | 87% - 90% | 87% - 90% | 88% - 90% | |||||
| R&D expenses | $3,000 - $3,300 | $3,000 - $3,300 | $2,800 - $3,000 | |||||
| SG&A expenses | $3,000 - $3,300 | $3,000 - $3,300 | $3,000 - $3,200 | |||||
| Effective Tax Rate | 18.0% - 20.0% | 18.0% - 20.0% | 17.0% - 18.0% | |||||
| Diluted EPS Impact of Acquisition-Related, Restructuring, Stock-Based Compensation Expenses and Other | $0.82 - $0.87 | $0.82 - $0.87 | $0.82 - $0.87 | |||||
| * Non-GAAP product gross margin, R&D and SG&A expenses and effective tax rate exclude amounts related to acquisition, restructuring, stock-based compensation and other. | ||||||||
Corporate Highlights
- Announced the signing of a definitive agreement to acquire EpiTherapeutics, a privately-held Danish company. EpiTherapeutics generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases.
-
Announced that the company’s Board of Directors declared a quarterly
cash dividend of
$633 million or$0.43 per share of common stock and paid onJune 29, 2015 to all stockholders of record as of the close of business on the record date ofJune 16, 2015 . This was the first quarterly dividend declared under the Board's dividend program announced onFebruary 3, 2015 .
Product & Pipeline Updates Announced by
Antiviral Program
-
Announced that Gilead submitted a New Drug Application (NDA) to the
U.S. Food and Drug Administration (FDA ) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) (200/10 mg and 200/25 mg) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents. Under the Prescription Drug User Fee Act, the FDA has set a target action date of April 7, 2016.-
This was Gilead's second F/TAF-based NDA submitted to the
FDA for review. In November 2014, Gilead filed an NDA for an investigational once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF). The FDA has set a target action date of November 5, 2015.
-
This was Gilead's second F/TAF-based NDA submitted to the
-
Announced that Gilead’s Marketing Authorization Application (MAA) for
two doses of F/TAF (200/10 mg and 200/25 mg) was fully validated and
under evaluation by the
European Medicines Agency . The data included in the application support the use of F/TAF for the treatment of HIV-1 infection in adults in combination with other HIV antiretroviral agents.-
Gilead's MAA for E/C/F/TAF was validated on
December 23, 2014 .
-
Gilead's MAA for E/C/F/TAF was validated on
-
Presented data at the 50th Annual Meeting of the
European Association for the Study of the Liver including:- Positive results from two studies evaluating the safety and efficacy of investigational uses of sofosbuvir-based regimens in HCV-infected patients with genotypes 2, 3, 4 and 5. Results from the BOSON study of sofosbuvir in combination with ribavirin or with pegylated interferon and ribavirin demonstrated high cure rates across all patients with genotypes 2 and 3. Separately, results from a Phase 2 study demonstrated the safety and efficacy of ledipasvir/sofosbuvir in patients with genotypes 4 or 5 infection.
- Positive results from several Phase 2 clinical studies evaluating investigational uses of ledipasvir/sofosbuvir and other sofosbuvir-based regimens for the treatment of HCV infection in patients with advanced liver disease, including patients with decompensated cirrhosis, patients with fibrosing cholestatic hepatitis C (a rare and severe form of the disease following liver transplantation) and patients with portal hypertension.
- Positive pre-clinical data and results from Phase 1 and Phase 2 studies supporting the development of an investigational all-oral, pan-genotypic regimen of sofosbuvir, the investigational NS5A inhibitor velpatasvir (formerly GS-5816) and GS-9857, an investigational NS3/4A protease inhibitor. In pre-clinical studies, GS-9857 demonstrated similarly potent antiviral activity against HCV replicons of all tested genotypes (1-6), as well as an improved resistance profile compared to other HCV protease inhibitors. In a healthy volunteer study, GS-9857 demonstrated a favorable pharmacokinetic profile. Data from a three-day monotherapy study also demonstrated that GS-9857 was well-tolerated for HCV patients with genotypes 1, 2, 3 and 4 at the 100 mg dose.
Oncology Program
-
Announced positive results from the Phase 3 clinical Study 119 of an
investigational use of Zydelig® (idelalisib) in combination with
ofatumumab in previously-treated patients with chronic lymphocytic
leukemia. In Study 119, there was a 73-percent reduction in the risk
of disease progression or death in patients receiving Zydelig in
combination with ofatumumab compared to ofatumumab alone. These
results were presented at the 51st Annual Meeting of the
American Society of Clinical Oncology .
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2015 financial results; Gilead's ability to
sustain growth in revenues for its antiviral and other programs;
availability of funding for state AIDS Drug Assistance Programs (ADAPs);
continued fluctuations in ADAP purchases driven by federal and state
grant cycles which may not mirror patient demand and may cause
fluctuations in Gilead's earnings; the possibility of unfavorable
results from clinical trials involving sofosbuvir-containing products,
including the pan-genotypic regimen of sofosbuvir, velpatasvir and
GS-9857; Gilead's ability to initiate clinical trials in its currently
anticipated timeframes; the levels of inventory held by wholesalers and
retailers which may cause fluctuations in Gilead's earnings; Gilead's
ability to submit new drug applications for new product candidates in
the timelines currently anticipated; Gilead's ability to receive
regulatory approvals in a timely manner or at all, for new and current
products, including F/TAF and E/C/F/TAF; Gilead's ability to
successfully commercialize its products; the risk that physicians and
patients may not see advantages of these products over other therapies
and may therefore be reluctant to prescribe the products; the risk that
estimates of patients with HCV or anticipated patient demand may not be
accurate; the risk that private and public payers may be reluctant to
provide, or continue to provide, coverage or reimbursement for new
products, including Sovaldi and Harvoni; Gilead's ability to
successfully develop its oncology, inflammation, cardiovascular and
respiratory programs, including the compounds purchased from
EpiTherapeutics; safety and efficacy data from clinical studies may not
warrant further development of Gilead's product candidates, including
the pan-genotypic regimen of sofosbuvir, velpatasvir and GS-9857; the
potential for additional austerity measures in European countries that
may increase the amount of discount required on Gilead's products;
Gilead's ability to complete its share repurchase program due to changes
in its stock price, corporate or other market conditions; Gilead’s
ability to pay dividends under its dividend program and the risk that
its Board of Directors may reduce the amount of the dividend;
fluctuations in the foreign exchange rate of the U.S. dollar that may
cause an unfavorable foreign currency exchange impact on Gilead's future
revenues and pre-tax earnings; and other risks identified from time to
time in Gilead's reports filed with the
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
For more information on
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions, except per share amounts) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 8,126 | $ | 6,413 | $ | 15,531 | $ | 11,284 | ||||||||
| Royalty, contract and other revenues | 118 | 122 | 307 | 250 | ||||||||||||
| Total revenues | 8,244 | 6,535 | 15,838 | 11,534 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 998 | 925 | 1,880 | 1,738 | ||||||||||||
| Research and development expenses | 818 | 584 | 1,514 | 1,179 | ||||||||||||
| Selling, general and administrative expenses | 812 | 614 | 1,457 | 1,162 | ||||||||||||
| Total costs and expenses | 2,628 | 2,123 | 4,851 | 4,079 | ||||||||||||
| Income from operations | 5,616 | 4,412 | 10,987 | 7,455 | ||||||||||||
| Interest expense | (140 | ) | (102 | ) | (293 | ) | (178 | ) | ||||||||
| Other income (expense), net | 35 | (4 | ) | 56 | (22 | ) | ||||||||||
| Income before provision for income taxes | 5,511 | 4,306 | 10,750 | 7,255 | ||||||||||||
| Provision for income taxes | 1,014 | 656 | 1,921 | 1,382 | ||||||||||||
| Net income | 4,497 | 3,650 | 8,829 | 5,873 | ||||||||||||
| Net income (loss) attributable to noncontrolling interest | 5 | (6 | ) | 4 | (10 | ) | ||||||||||
| Net income attributable to Gilead | $ | 4,492 | $ | 3,656 | $ | 8,825 | $ | 5,883 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 3.05 | $ | 2.39 | $ | 5.96 | $ | 3.83 | ||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 2.92 | $ | 2.20 | $ | 5.68 | $ | 3.52 | ||||||||
| Shares used in per share calculation - basic | 1,472 | 1,533 | 1,480 | 1,535 | ||||||||||||
| Shares used in per share calculation - diluted | 1,540 | 1,664 | 1,555 | 1,672 | ||||||||||||
| Cash dividends declared per share | $ | 0.43 | $ | — | $ | 0.43 | $ | — | ||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 998 | $ | 925 | $ | 1,880 | $ | 1,738 | ||||||||
| Stock-based compensation expenses | (3 | ) | (2 | ) | (6 | ) | (5 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (207 | ) | (200 | ) | (413 | ) | (399 | ) | ||||||||
| Variable interest entity consolidated costs(1) | — | — | 1 | — | ||||||||||||
| Non-GAAP cost of goods sold | $ | 788 | $ | 723 | $ | 1,462 | $ | 1,334 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 87.7 | % | 85.6 | % | 87.9 | % | 84.6 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 2.5 | % | 3.1 | % | 2.7 | % | 3.5 | % | ||||||||
| Non-GAAP product gross margin(2) | 90.3 | % | 88.7 | % | 90.6 | % | 88.2 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 818 | $ | 584 | $ | 1,514 | $ | 1,179 | ||||||||
| Stock-based compensation expenses | (42 | ) | (37 | ) | (84 | ) | (71 | ) | ||||||||
| Acquisition related expenses | (67 | ) | — | (67 | ) | — | ||||||||||
| Acquisition related-contingent consideration remeasurement | (7 | ) | (5 | ) | (10 | ) | (8 | ) | ||||||||
| Non-GAAP research and development expenses | $ | 702 | $ | 542 | $ | 1,353 | $ | 1,100 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 812 | $ | 614 | $ | 1,457 | $ | 1,162 | ||||||||
| Stock-based compensation expenses | (51 | ) | (44 | ) | (98 | ) | (90 | ) | ||||||||
| Restructuring expenses | — | — | 2 | — | ||||||||||||
| Acquisition related-amortization of purchased intangibles | — | — | — | (2 | ) | |||||||||||
| Non-GAAP selling, general and administrative expenses | $ | 761 | $ | 570 | $ | 1,361 | $ | 1,070 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 68.1 | % | 67.5 | % | 69.4 | % | 64.6 | % | ||||||||
| Stock-based compensation expenses | 1.2 | % | 1.3 | % | 1.2 | % | 1.4 | % | ||||||||
| Acquisition related expenses | 0.8 | % | — | % | 0.4 | % | — | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 2.5 | % | 3.1 | % | 2.6 | % | 3.5 | % | ||||||||
| Acquisition related-contingent consideration remeasurement | 0.1 | % | 0.1 | % | 0.1 | % | 0.1 | % | ||||||||
| Non-GAAP operating margin(2) | 72.7 | % | 71.9 | % | 73.6 | % | 69.6 | % | ||||||||
| Other income (expense) reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | 35 | $ | (4 | ) | $ | 56 | $ | (22 | ) | ||||||
| Acquisition related-transaction costs | — | — | — | (2 | ) | |||||||||||
| Non-GAAP other income (expense), net | $ | 35 | $ | (4 | ) | $ | 56 | $ | (24 | ) | ||||||
| Notes: | ||||||||||||||||
| Immaterial amounts are not presented in the tables above | ||||||||||||||||
| (1) Consolidation of a contract manufacturer | ||||||||||||||||
(2) Amounts may not sum due to rounding | ||||||||||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 18.4 | % | 15.2 | % | 17.9 | % | 19.1 | % | ||||||||
| Acquisition related expenses/transaction costs | (0.2 | )% | — | % | (0.1 | )% | — | % | ||||||||
| Acquisition related-amortization of purchased intangibles | (0.5 | )% | (0.6 | )% | (0.5 | )% | (0.9 | )% | ||||||||
| Non-GAAP effective tax rate(1) | 17.7 | % | 14.6 | % | 17.3 | % | 18.2 | % | ||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead | $ | 4,492 | $ | 3,656 | $ | 8,825 | $ | 5,883 | ||||||||
| Stock-based compensation expenses | 71 | 72 | 140 | 136 | ||||||||||||
| Restructuring expenses | — | — | (2 | ) | — | |||||||||||
| Acquisition related expenses/transaction costs | 67 | — | 67 | (1 | ) | |||||||||||
| Acquisition related-amortization of purchased intangibles | 202 | 196 | 403 | 391 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 7 | 5 | 10 | 8 | ||||||||||||
| Variable interest entity consolidated costs(2) | 6 | — | 6 | — | ||||||||||||
| Non-GAAP net income attributable to Gilead | $ | 4,845 | $ | 3,929 | $ | 9,449 | $ | 6,417 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 2.92 | $ | 2.20 | $ | 5.68 | $ | 3.52 | ||||||||
| Stock-based compensation expenses | 0.05 | 0.04 | 0.09 | 0.08 | ||||||||||||
| Acquisition related expenses/transaction costs | 0.04 | — | 0.04 | — | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 0.13 | 0.12 | 0.26 | 0.23 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | — | — | 0.01 | — | ||||||||||||
| Non-GAAP diluted earnings per share(1) | $ | 3.15 | $ | 2.36 | $ | 6.08 | $ | 3.84 | ||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,540 | 1,664 | 1,555 | 1,672 | ||||||||||||
| Share impact of current stock-based compensation rules | — | (1 | ) | — | (1 | ) | ||||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,540 | 1,663 | 1,555 | 1,671 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 210 | $ | 202 | $ | 418 | $ | 404 | ||||||||
| Research and development expenses adjustments | 116 | 42 | 161 | 79 | ||||||||||||
| Selling, general and administrative expenses adjustments | 51 | 44 | 96 | 92 | ||||||||||||
| Other income (expense) adjustments | — | — | — | (2 | ) | |||||||||||
| Total non-GAAP adjustments before tax | 377 | 288 | 675 | 573 | ||||||||||||
| Income tax effect | (30 | ) | (14 | ) | (58 | ) | (38 | ) | ||||||||
| Variable interest entity consolidated costs(2) | 6 | — | 7 | — | ||||||||||||
| Total non-GAAP adjustments after tax attributable to Gilead | $ | 353 | $ | 274 | $ | 624 | $ | 535 | ||||||||
| Notes: | ||||||||||||||||
| Immaterial amounts are not presented in the tables above | ||||||||||||||||
| (1) Amounts may not sum due to rounding | ||||||||||||||||
| (2) Consolidation of a contract manufacturer | ||||||||||||||||
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) | |||||||
June 30, | December 31, | ||||||
| 2015 | 2014(1) | ||||||
| Cash, cash equivalents and marketable securities | $ | 14,667 | $ | 11,726 | |||
| Accounts receivable, net | 5,331 | 4,635 | |||||
| Inventories | 2,039 | 1,386 | |||||
| Property, plant and equipment, net | 1,899 | 1,674 | |||||
| Intangible assets, net | 10,660 | 11,073 | |||||
| Goodwill | 1,172 | 1,172 | |||||
| Other assets | 3,399 | 2,998 | |||||
| Total assets | $ | 39,167 | $ | 34,664 | |||
| Current liabilities | $ | 8,925 | $ | 5,761 | |||
| Long-term liabilities | 13,601 | 13,069 | |||||
| Equity component of currently redeemable convertible notes | 7 | 15 | |||||
| Stockholders’ equity(2) | 16,634 | 15,819 | |||||
| Total liabilities and stockholders’ equity | $ | 39,167 | $ | 34,664 | |||
| Notes: | |||||||
(1) Derived from the audited consolidated financial statements as of December 31, 2014. | |||||||
(2) As of June 30, 2015, there were 1,473 million shares of common stock issued and outstanding. | |||||||
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in millions) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2015 | 2014 | 2015 | 2014 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Harvoni – U.S. | $ | 2,826 | $ | — | $ | 5,842 | $ | — | |||||||
| Harvoni – Europe | 623 | — | 1,100 | — | |||||||||||
| Harvoni – Other International | 159 | — | 245 | — | |||||||||||
| 3,608 | — | 7,187 | — | ||||||||||||
| Sovaldi – U.S. | 615 | 3,031 | 1,036 | 5,129 | |||||||||||
| Sovaldi – Europe | 522 | 401 | 1,005 | 564 | |||||||||||
| Sovaldi – Other International | 154 | 49 | 222 | 62 | |||||||||||
| 1,291 | 3,481 | 2,263 | 5,755 | ||||||||||||
| Truvada – U.S. | 500 | 399 | 909 | 767 | |||||||||||
| Truvada – Europe | 277 | 338 | 578 | 661 | |||||||||||
| Truvada – Other International | 72 | 69 | 133 | 138 | |||||||||||
| 849 | 806 | 1,620 | 1,566 | ||||||||||||
| Atripla – U.S. | 549 | 578 | 1,043 | 1,068 | |||||||||||
| Atripla – Europe | 178 | 234 | 372 | 471 | |||||||||||
| Atripla – Other International | 55 | 58 | 101 | 111 | |||||||||||
| 782 | 870 | 1,516 | 1,650 | ||||||||||||
| Stribild – U.S. | 364 | 230 | 646 | 417 | |||||||||||
| Stribild – Europe | 65 | 31 | 126 | 55 | |||||||||||
| Stribild – Other International | 18 | 9 | 31 | 13 | |||||||||||
| 447 | 270 | 803 | 485 | ||||||||||||
| Complera / Eviplera – U.S. | 207 | 153 | 370 | 284 | |||||||||||
| Complera / Eviplera – Europe | 145 | 132 | 290 | 241 | |||||||||||
| Complera / Eviplera – Other International | 15 | 14 | 27 | 25 | |||||||||||
| 367 | 299 | 687 | 550 | ||||||||||||
| Viread – U.S. | 134 | 117 | 234 | 198 | |||||||||||
| Viread – Europe | 77 | 88 | 157 | 172 | |||||||||||
| Viread – Other International | 60 | 56 | 114 | 102 | |||||||||||
| 271 | 261 | 505 | 472 | ||||||||||||
| Other Antiviral – U.S. | 8 | 13 | 22 | 20 | |||||||||||
| Other Antiviral – Europe | 7 | 10 | 14 | 19 | |||||||||||
| Other Antiviral – Other International | 1 | 2 | 2 | 4 | |||||||||||
| 16 | 25 | 38 | 43 | ||||||||||||
| Total antiviral products – U.S. | 5,203 | 4,521 | 10,102 | 7,883 | |||||||||||
| Total antiviral products – Europe | 1,894 | 1,234 | 3,642 | 2,183 | |||||||||||
| Total antiviral products – Other International | 534 | 257 | 875 | 455 | |||||||||||
| 7,631 | 6,012 | 14,619 | 10,521 | ||||||||||||
| Other products: | |||||||||||||||
| Letairis | 176 | 145 | 327 | 268 | |||||||||||
| Ranexa | 141 | 123 | 258 | 234 | |||||||||||
| AmBisome | 103 | 94 | 188 | 186 | |||||||||||
| Zydelig | 30 | — | 56 | — | |||||||||||
| Other | 45 | 39 | 83 | 75 | |||||||||||
| 495 | 401 | 912 | 763 | ||||||||||||
| Total product sales | $ | 8,126 | $ | 6,413 | $ | 15,531 | $ | 11,284 | |||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006596/en/
Source:
Gilead Sciences, Inc.Robin Washington, 650-522-5688 (Investors)Patrick O'Brien, 650-522-1936 (Investors)Amy Flood, 650-522-5643 (Media)
Other News
Some of the content on this page is not intended for users outside the U.S.